Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
NCT06466785Phase 3Recruiting
- Sponsor
- Genexine
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 11
01
Overview
Phase 3, randomised, single-blind trial of epoetin alfa in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Genexine. Primary endpoint: Mean change in hemoglobin. Started Jan 2024; status: recruiting.
02
Drugs
epoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT06466785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06466785.